HEAL - ETF AI Analysis
Top Page
Global X HealthTech ETF (HEAL)
Rating:62Neutral
Price Target:―
Positive Factors
Leading HealthTech Focus
The fund targets companies at the intersection of health care and technology, giving investors focused exposure to a growing niche of the market.
Strong Contribution From Top Holding Masimo
Masimo, the largest position in the ETF, has shown strong year-to-date performance, helping offset weakness in some other holdings.
Global Diversification Beyond the U.S.
While most assets are in U.S. companies, the fund also holds stocks from Europe, Asia, and Australia, adding some international diversification.
Negative Factors
Recent Weak Overall Performance
The ETF has delivered negative returns so far this year and over the last three months, indicating recent performance has been weak.
High Concentration In Health Care Sector
With the vast majority of assets in health care, the fund is heavily exposed to sector-specific risks such as regulatory changes and reimbursement pressures.
Several Key Holdings Are Lagging
Many of the larger positions, including Dexcom, GE Healthcare, TransMedics, Resmed, Alibaba Health, IQVIA, and Intuitive Surgical, have shown weak year-to-date performance, which can drag on the fund’s returns.
HEAL vs. SPDR S&P 500 ETF (SPY)
AUM25.26M
RegionGlobal
Expense Ratio0.50%
Beta1.07
IssuerGlobal X
Inception DateJul 29, 2020
Dividend Yield0.38%
Asset ClassEquity
Index TrackedGlobal X HealthTech Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume9,708
30 Day Avg. Volume12,723
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
34.05Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering40
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HEAL Summary
HEAL, the Global X HealthTech ETF, tracks the Global X HealthTech Index and focuses on companies using technology to improve healthcare. It holds businesses involved in telemedicine, digital health platforms, and remote monitoring tools. Well-known names in the fund include Philips and Intuitive Surgical. Someone might invest in HEAL if they believe digital healthcare will keep growing and want a simple way to spread their money across many health-tech companies instead of picking individual stocks. A key risk is that it is heavily focused on healthcare technology, so its price can swing a lot if this niche falls out of favor.
How much will it cost me?The Global X HealthTech ETF (HEAL) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like health technology, which requires more research and expertise.
What would affect this ETF?The Global X HealthTech ETF (EDOC) could benefit from increasing demand for telemedicine and digital health solutions as healthcare systems worldwide continue to embrace technology for efficiency and accessibility. However, potential risks include regulatory changes in healthcare technology or slower adoption rates in certain regions, which could impact the growth of companies in its portfolio. Additionally, economic downturns or rising interest rates might negatively affect the performance of smaller, innovative firms within the ETF.
HEAL Top 10 Holdings
HEAL is a pure play on global digital health, with nearly all its firepower in healthcare names rather than broad tech. Masimo and Philips have been relatively steady to rising, helping to prop up returns, while Alignment Healthcare has recently sprinted ahead and adds some growth flair. On the flip side, heavyweights like Dexcom, Intuitive Surgical, and IQVIA have been losing altitude, acting as a drag despite solid long-term stories. With exposure spread across the U.S., Europe, and Asia, performance is driven more by the healthtech theme than any single country.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Masimo | 5.89% | $1.51M | $9.35B | 8.91% | 54 Neutral | |
| Dexcom | 5.29% | $1.35M | $23.76B | -13.72% | 79 Outperform | |
| Koninklijke Philips N.V. | 4.59% | $1.17M | €22.14B | 5.40% | 56 Neutral | |
| GE Healthcare Technologies Inc | 4.46% | $1.14M | $31.41B | 3.54% | 78 Outperform | |
| TransMedics Group | 4.40% | $1.13M | $3.83B | 19.88% | 77 Outperform | |
| Resmed | 4.14% | $1.06M | $32.03B | -5.18% | 76 Outperform | |
| Intuitive Surgical | 4.05% | $1.04M | $170.78B | -8.37% | 78 Outperform | |
| Alignment Healthcare | 3.97% | $1.01M | $4.32B | 18.43% | 60 Neutral | |
| Alibaba Health Information Technology | 3.83% | $979.66K | HK$73.90B | 2.48% | 63 Neutral | |
| IQVIA Holdings | 3.64% | $930.84K | $27.54B | 9.13% | 73 Outperform |
HEAL Technical Analysis
Neutral
―
Price Trends
25.23
Positive
27.21
Negative
29.36
Negative
Market Momentum
0.08
Positive
50.77
Neutral
24.28
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HEAL, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 25.23, equal to the 50-day MA of 25.23, and equal to the 200-day MA of 29.36, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 50.77 is Neutral, neither overbought nor oversold. The STOCH value of 24.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HEAL.
HEAL Peer Comparison
Comparison Results
Performance Comparison
HEAL
Global X HealthTech ETF
25.33
-4.84
-16.04%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents